Company Overview of Aragon Pharmaceuticals, Inc.
Aragon Pharmaceuticals, Inc. develops medicines for the treatment of hormonally-driven cancers such as prostate and breast cancer. It develops ARN-509, a compound for the treatment of castration-resistant prostate cancer. It also develops selective androgen receptor degraders and selective estrogen receptor degraders that prevent cancer growth by inhibiting hormone action on the receptor and inducing receptor degradation; and ARN-810, an oral selective estrogen receptor degrader for the treatment of locally advanced or metastatic estrogen receptor positive breast cancer in post-menopausal women. The company was founded in 2009 and is based in San Diego, California. As of August 19, 2013, Ara...
12780 El Camino Real
San Diego, CA 92130
Founded in 2009
Key Executives for Aragon Pharmaceuticals, Inc.
Co-Founder and Scientific Advisor
Vice President of Finance
Compensation as of Fiscal Year 2014.
Aragon Pharmaceuticals, Inc. Key Developments
Aragon Pharmaceuticals, Inc. Presents at Jefferies 2013 Global Healthcare Conference, Jun-05-2013 08:00 AM
May 21 13
Aragon Pharmaceuticals, Inc. Presents at Jefferies 2013 Global Healthcare Conference, Jun-05-2013 08:00 AM. Venue: Grand Hyatt Hotel, 109 East 42nd Street at Grand Central, New York, New York, United States. Speakers: Paul B. Cleveland, Chief Financial Officer and Executive Vice President of Corporate Strategy.
Aragon Pharmaceuticals, Inc. Announces First Patient Dosed in Phase I Study of ARN-810 in Estrogen Receptor Positive Breast Cancer
Apr 4 13
Aragon Pharmaceuticals, Inc. announced that the first patient has been dosed in a Phase I clinical study of ARN-810, an oral selective estrogen receptor degrader (SERD), for the treatment of locally advanced or metastatic estrogen receptor positive breast cancer in post-menopausal women. Approximately 70% of breast cancers are dependent on estrogen for growth and survival. Current treatment generally involves antihormonal therapies, such as tamoxifen or aromatase inhibitors. Although these therapies are initially effective, acquired resistance is common, leading to disease progression. ARN-810 is a potent, orally bioavailable nonsteroidal agent, which functions by binding to the estrogen receptor, inducing a conformational change resulting in the degradation of the receptor. As such, its novel profile represents a new treatment that may circumvent resistance seen in traditional therapies. The Phase 1 dose escalation study is designed to assess safety and tolerability of ARN-810. The study will be conducted at Vanderbilt University, Mass General Hospital and Memorial Sloan-Kettering Cancer Center.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries